Sudocrem boss: new skin drug will net €1.5bn - Raglan Capital

Home
About Us
- Why Raglan
- Careers
Selected Transactions
Fundraising and Financial Support
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Sudocrem boss: new skin drug will net €1.5bn

Home
Amryt Pharma
Sudocrem boss: new skin drug will net €1.5bn

Recent News

Open Orphan in German pharma deal
Open Orphan signs ‘significant’ revenue generating contract
Open Orphan in line to take stake in ‘$1bn’ flu drug
Amryt says integration of acquired company Aegerion ‘progressing well’
Open Orphan recruits hVIVO for its rare disease mission
Open Orphan to buy hVIVO in £30m merger deal

10 April 2016

Sudocrem boss: new skin drug will net €1.5bn 10 April 2016 online article

Add comment Cancel reply

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Prev
Next

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 (01) 6440007
E: info@raglancapital.ie

Email us for our newsletters

Contact us
Careers

Share our site